AR028023A1 - Una composicion farmaceutica para el tratamiento de la hiperlipidemia y el uso de dicha composicion para la preparacion de medicamentos - Google Patents

Una composicion farmaceutica para el tratamiento de la hiperlipidemia y el uso de dicha composicion para la preparacion de medicamentos

Info

Publication number
AR028023A1
AR028023A1 ARP010101847A ARP010101847A AR028023A1 AR 028023 A1 AR028023 A1 AR 028023A1 AR P010101847 A ARP010101847 A AR P010101847A AR P010101847 A ARP010101847 A AR P010101847A AR 028023 A1 AR028023 A1 AR 028023A1
Authority
AR
Argentina
Prior art keywords
composition
hyperlipidemia
medicines
preparation
treatment
Prior art date
Application number
ARP010101847A
Other languages
English (en)
Original Assignee
Borody Thomas J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPQ6969A external-priority patent/AUPQ696900A0/en
Priority claimed from AUPR0851A external-priority patent/AUPR085100A0/en
Application filed by Borody Thomas J filed Critical Borody Thomas J
Publication of AR028023A1 publication Critical patent/AR028023A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
ARP010101847A 2000-04-19 2001-04-19 Una composicion farmaceutica para el tratamiento de la hiperlipidemia y el uso de dicha composicion para la preparacion de medicamentos AR028023A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ6969A AUPQ696900A0 (en) 2000-04-19 2000-04-19 Novel therapy for hyperlipidaemia-associated disorders
AUPR0851A AUPR085100A0 (en) 2000-10-19 2000-10-19 Novel therapy for hyperlipidaemia-associated disorders

Publications (1)

Publication Number Publication Date
AR028023A1 true AR028023A1 (es) 2003-04-23

Family

ID=25646303

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101847A AR028023A1 (es) 2000-04-19 2001-04-19 Una composicion farmaceutica para el tratamiento de la hiperlipidemia y el uso de dicha composicion para la preparacion de medicamentos

Country Status (10)

Country Link
US (2) US20040009961A1 (es)
EP (1) EP1284723A4 (es)
JP (1) JP2003531171A (es)
AR (1) AR028023A1 (es)
BR (1) BR0110208A (es)
CA (1) CA2406067A1 (es)
MX (1) MXPA02010316A (es)
NZ (1) NZ522036A (es)
PL (1) PL357674A1 (es)
WO (1) WO2001080852A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
EP1388352A1 (en) 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
GB0309154D0 (en) 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
WO2005046662A2 (en) 2003-11-07 2005-05-26 Jj Pharma, Inc. Hdl-boosting combination therapy complexes
EP1811991B1 (en) 2004-11-10 2018-11-07 Genzyme Corporation Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis
ES2546181T3 (es) * 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
EP2594562B1 (en) 2007-05-31 2016-07-20 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
CN101888840A (zh) 2007-10-05 2010-11-17 简詹姆公司 使用脑酰胺衍生物治疗多囊性肾疾病的方法
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
RU2578947C2 (ru) 2008-10-03 2016-03-27 Джензайм Корпорейшн Ингибиторы глюкозилцерамидсинтазы 2-ациламинопропанольного типа
KR101072600B1 (ko) * 2009-04-09 2011-10-11 한올바이오파마주식회사 플루바스타틴을 포함하는 안정한 약제학적 조성물 및 그의 제조방법
KR100980749B1 (ko) * 2009-12-17 2010-09-07 삼일제약주식회사 페노피브레이트-함유 과립 및 이를 포함하는 약학 조성물
KR100980752B1 (ko) * 2009-12-17 2010-09-07 삼일제약주식회사 담체 표면 상에 흡착된 페노피브레이트를 포함하는 과립 및 이를 포함하는 약학 조성물
NZ611868A (en) 2010-12-13 2015-11-27 Salix Pharmaceuticals Inc Gastric and colonic formulations and methods for making and using them
JP6030147B2 (ja) 2011-11-30 2016-11-24 デウン ファーマシューティカル カンパニー リミテッド 高トリグリセリド血症または高トリグリセリド血症に関連する疾患を予防または治療するための医薬組成物
WO2013169648A1 (en) 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
RU2015106688A (ru) 2012-07-27 2016-09-20 Редхилл Байофарма Лтд. Препараты и способы получения препаратов для применения при опорожнении толстой кишки
BR112017016766B1 (pt) * 2015-02-06 2023-11-07 Intercept Pharmaceuticals, Inc Composição compreendendo um agonista fxr e fibrato, bem como uso para tratar doença hepática colestática

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2924562C3 (de) * 1979-06-19 1982-04-29 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Lipide senkendes Arzneimittel
GB9013448D0 (en) * 1990-06-15 1990-08-08 Sandoz Ltd Pharmaceutical resorption-improved somatostatin compositions,their preparation and use
IT1245890B (it) * 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
US5763435A (en) * 1995-11-21 1998-06-09 Children's Hospital Medical Center Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders
JP2002533411A (ja) * 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するための組み合わせ
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin

Also Published As

Publication number Publication date
US20080286354A1 (en) 2008-11-20
CA2406067A1 (en) 2001-11-01
BR0110208A (pt) 2003-01-28
EP1284723A4 (en) 2004-06-30
NZ522036A (en) 2004-04-30
US20040009961A1 (en) 2004-01-15
MXPA02010316A (es) 2005-04-19
JP2003531171A (ja) 2003-10-21
EP1284723A1 (en) 2003-02-26
PL357674A1 (en) 2004-07-26
WO2001080852A1 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
AR028023A1 (es) Una composicion farmaceutica para el tratamiento de la hiperlipidemia y el uso de dicha composicion para la preparacion de medicamentos
NO20020464L (no) Flerkomponents farmasöytisk doseringsform
ATE355271T1 (de) Pharmazeutische zusammensetzung
DE60106623D1 (de) Neue pharmazeutische zusammensetzung
DE60201988D1 (de) Pharmazeutische dosierungsform von amorphem nilfenavir mesylat
NO20030627D0 (no) Hydrogel-drevet medikament doseringsform
EE200000383A (et) Peroraalne farmatseutiline pikendatud vabanemisega annusvorm
ATE331529T1 (de) Antigen enthaltende pharmazeutische zusammensetzung
NO20022970D0 (no) Hydrogel-drevet medikamentdoseringsform
ITTO20010008A0 (it) Formulazione farmaceutica
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
DK1158992T3 (da) Anvendelse af xenon til fremstilling af et farmaceutisk præparat til behandling af neurointoksikationer
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
ATE320244T1 (de) Pharmazeutische zusammensetzungen mit amlodipinmaleat
ECSP045171A (es) Régimen de dosificación y composición farmacéutica para anticoncepción de emergencia
EE05020B1 (et) Glburiidi ravimkoostis
DE60037816D1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
AR028588A1 (es) Forma de administracion farmaceutica para peptidos, procedimiento para su preparacion y uso
FI20000780A (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
ATE366128T1 (de) Pharmazeutische zusammensetzung
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE60121293D1 (de) Pharmazeutische zusammensetzungen, welche steroidische strukturen enthalten, und deren verwendungen
DE10291905D2 (de) Pharmazeutische Zusammensetzung
EE200200480A (et) Memnopeptiidühend, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain

Legal Events

Date Code Title Description
FB Suspension of granting procedure